Spots Global Cancer Trial Database for Identify Prognostic Biomarkers of Lung Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Identify Prognostic Biomarkers of Lung Cancer

Official Title: Multi-omics Combined With Clinical Data Analysis to Identify Prognostic Biomarkers of Lung Cancer

Study ID: NCT05010330

Conditions

Lung Cancer

Lung Adenocarcinoma

Lung Squamous Cell Carcinoma

Non Small Cell Lung Cancer

Interventions

Study Description

Brief Summary: Multi-omics and Clinical Data Analysis is potential to predict the prognosis of lung cancer patients.

Detailed Description: Lung cancer is the leading cause of cancer-related death in China. In order to improve prognosis of lung cancer as well as provide new therapeutic targets, the identification of effective biomarkers for the prognosis of lung cancer is of great significance. It has been reported that some small molecules such as lncRNA, circRNA and polypeptides in human plasm have good prospects in diagnosing or evaluating the stage of diseases. In this study, we planned to use multi-omics combined with clinical data to discovery some small molecules that are potential to predict the prognosis of lung cancer patients. In addition, we want to construct a new risk score model that provide a candidate model for prognostic evaluation of lung cancer. And we hope our study can provide insights for precision immunotherapy of lung cancer by exploring the differences in clinical characteristics, tumor mutation burden, and tumor immune cell infiltration between different risk score groups.